EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib

L M Chen, S C H Yu, L Li, E P Hui, W Yeo, S L Chan

Hong Kong Medical Journal · 2025

DOI: 10.12809/hkmj2311239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hong Kong Medical Journal, 2025. Verfasst von L M Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Chemoembolization, Therapeutic. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularSorafenibLiver NeoplasmsChemoembolization, TherapeuticAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedTumor BurdenHong KongRetrospective StudiesNeoplasm StagingLiver Function TestsBilirubinAdult

Stichwörter der Autor:innen

Carcinoma, hepatocellularChemoembolization, therapeuticPatient selectionTumor burden

Substanzen

SorafenibAntineoplastic AgentsBilirubin

Autor:innen und Institutionen

  • Department of Imaging and Interventional Radiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Medical Ultrasonics, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • State Key Laboratory of Translational Oncology, China.

Zitieren

APA

Chen, L. M., Yu, S. C. H., Li, L., Hui, E. P., Yeo, W., & Chan, S. L. (2025). Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib. Hong Kong Medical Journal. https://doi.org/10.12809/hkmj2311239

Vancouver

Chen LM, Yu SCH, Li L, Hui EP, Yeo W, Chan SL. Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib. Hong Kong Medical Journal. 2025. doi:10.12809/hkmj2311239

BibTeX
@article{Chen2025,
  author = {Chen, L M and Yu, S C H and Li, L and Hui, E P and Yeo, W and Chan, S L},
  title = {Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib},
  journal = {Hong Kong Medical Journal},
  year = {2025},
  doi = {10.12809/hkmj2311239}
}
Kostenlos starten →